retatrutide constipation Side Effects: What Patients Should Know Retatrutide side effects: GI, heart,

Semaglutide is a glucagon-like peptide-1 reception agonist, mimicking the GLP-1 hormone, which is typically released in response to eating

Specifically, in the group of patients prescribed semaglutide for weight loss, 6.7% developed NAION compared to just 0.8% of those on other treatments

Many participants were using other diabetes medications prior to the trial, highlighting the challenge of achieving control with conventional approaches

Month 1 Summary: What Was Accomplished Weight loss: 2-4 pounds average (1-2% of starting weight) Appetite change: 60-70% report noticeable suppression Side effects: Mild to moderate in 40% of people, minimal in 60% Discontinuation rate: 3-5% stop during month 1 (lowest attrition period) Psychological state: Hopeful but impatient for faster results Key achievement: Body adapted to medication without major complications Reality check: Month 1 is the easiest month

This class of medications contains the popular semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)